10-Q: SI-BONE Q2 2025: Revenue Surges, Losses Narrow

SI-BONE, Inc. reported a significant 21.7% increase in Q2 2025 revenue and a reduced net loss, driven by expanded product offerings and increased U.S. surgical volumes.

Summary

• Revenue for the three months ended June 30, 2025, increased by 21.7% to $48.6 million, up from $39.9 million in the same period last year.
• Gross profit rose by 22.9% to $38.8 million for Q2 2025, with gross margin improving to 79.8% from 79.0% in Q2 2024.
• Net loss for Q2 2025 significantly narrowed to $6.2 million, an improvement from a net loss of $8.9 million in Q2 2024.
• For the six months ended June 30, 2025, revenue increased by 23.2% to $95.9 million, compared to $77.8 million in the prior year period.
• Net cash used in operating activities for the six months ended June 30, 2025, substantially improved to $4.7 million, down from $13.9 million in the same period last year.
• The U.S. sales force expanded its clinical support specialists to 75 (from 67) and third-party sales agents to 295 (from 204) as of June 30, 2025.
• Over 3,600 U.S. physicians and 1,100 international physicians have been trained on the company's products and treated at least one patient as of June 30, 2025.
• Trailing twelve-month average revenue per territory sales manager increased to approximately $2.1 million as of June 30, 2025, from $1.7 million as of June 30, 2024.
• Clinical trial results for SAFFRON (iFuse TORQ for sacral fragility fractures) were published in May 2025, showing higher mobility recovery with surgical treatment.
• Early results from the STACI study (iFuse TORQ for SI joint dysfunction by interventional physicians) were published in June 2025, indicating a low adverse event rate and early improvement in pain and function.

Sentiment

Score: 7

Explanation: The company shows strong operational performance with significant revenue growth, improved gross margins, and a notable reduction in net loss and operating cash burn. This indicates positive momentum and effective cost management. However, the presence of an ongoing DOJ investigation and uncertainties surrounding CPT code reimbursement changes introduce material risks that temper overall sentiment, preventing a higher score.

Positives

• Strong revenue growth of 21.7% in Q2 2025 and 23.2% for the six months ended June 30, 2025, primarily driven by increased U.S. case volumes and an expanded product portfolio.
• Improved gross margin to 79.8% in Q2 2025, up from 79.0% in Q2 2024, due to lower product costs.
• Significant reduction in net loss for both the quarter ($6.2 million vs. $8.9 million) and six-month period ($12.7 million vs. $19.8 million), indicating progress towards profitability.
• Substantial improvement in cash flow from operating activities, with net cash used decreasing from $13.9 million to $4.7 million for the six-month period.
• Continued expansion of the U.S. sales force, particularly clinical support specialists and third-party sales agents, enhancing surgical capacity.
• Increased physician adoption and training, with over 3,600 U.S. physicians and 1,100 international physicians trained.
• Demonstrated increased sales force productivity, with revenue per territory sales manager rising to $2.1 million.
• Positive clinical trial results published for SAFFRON and STACI studies, reinforcing product efficacy and safety, which is crucial for market adoption and reimbursement.

Negatives

• Continued net losses, with an accumulated deficit of $444.0 million as of June 30, 2025.
• General and administrative expenses increased significantly by 28.7% in Q2 2025 and 25.3% for the six months, primarily due to higher personnel costs, stock-based compensation, legal, and consulting fees.
• Interest income decreased due to lower investment balances.
• Inventory increased to $34.2 million as of June 30, 2025, from $27.1 million as of December 31, 2024, indicating higher inventory build-up.
• Cash and marketable securities decreased slightly from $150.0 million at December 31, 2024, to $145.5 million at June 30, 2025.

Risks

• Disruptions in the supply of materials and components (e.g., titanium due to geopolitical events like Russia/Ukraine conflict) or sterilization services by third-party suppliers could adversely affect business operations and increase costs.
• Volatility in the common stock price due to macroeconomic factors, inflation, interest rate increases, economic downturns, clinical trial results, regulatory actions, competition, and litigation.
• Inadequate funding or disruptions at the FDA and other government agencies could hinder product development, commercialization, and regulatory reviews.
• Limited access to credit on favorable terms, if needed, could impact the ability to fund operations and capital projects.
• Uncertainty in the coverage and reimbursement environment, particularly regarding CPT codes 27279 and 27278 for sacroiliac joint fusion, could decrease demand for products if code definitions change or confusion arises.
• Ongoing civil investigative demand (CID) from the U.S. Department of Justice regarding potential Anti-Kickback Statute and Civil False Claims Act violations related to meals and consulting service payments to healthcare professionals, with an unknown duration or financial impact.

Future Outlook

The company expects to continue making investments in research and development to bring new and differentiated solutions to market. It anticipates certain operating expenses will increase to support growth. The company believes its existing cash and marketable securities will fund operating expenses and capital expenditure requirements for the next 12 months, but acknowledges potential challenges from economic downturns or capital market disruptions that could accelerate capital consumption.

Management Comments

• We are focused on increasing our sales managers' capacity and driving sales force productivity by adding more clinical support specialists and implementing hybrid models, including selectively adding third-party sales agents for case coverage, and by placing instrument trays and implants at select sites of service.
• We continue to actively engage with ambulatory surgery centers (ASCs) or Office-Based Labs (OBLs) to educate their management groups on our clinical evidence, exclusive commercial payor coverage and focus on driving improved education and pathways between pain physicians and surgeons.
• Robust clinical evidence is central to drive adoption and favorable reimbursement, and we remain focused on continuing to set the industry standard in delivering evidence-based care through best-in-class clinical trials that demonstrate the efficacy, safety, and economic benefit of our solutions.
• We are working closely with our suppliers to reduce lead time for our implants to ensure we can support our expanding physician footprint and over time build the resilience in our supply chain to reduce our cash investment in inventory.
• We are partnering with our suppliers around design for manufacturing, specifically for newer products, to reduce the overall cost of the implants as we scale, and reduce waste and rework.

Industry Context

The company operates in the medical device industry, specifically focusing on sacropelvic solutions and minimally invasive surgical implant systems. Its strategy aligns with broader industry trends of expanding product portfolios, increasing physician engagement through training, and leveraging clinical evidence for market building and favorable reimbursement. The shift towards procedures being performed at ambulatory surgery centers (ASCs) or Office-Based Labs (OBLs) is a key industry trend that the company is actively engaging with. The company's focus on supply chain resilience and cost reduction for implants reflects ongoing industry challenges related to global supply disruptions and inflation.

Management Changes

Corporate Governance

Legal Proceedings

• Received a civil investigative demand (CID) from the U.S. Department of Justice, Civil Division, in October 2024.
• The CID is in connection with an investigation under the federal Anti-Kickback Statute and Civil False Claims Act.
• The investigation primarily relates to meals and consulting service payments provided to health care professionals.
• The company is cooperating with the investigation but is currently unable to express a view regarding its likely duration, ultimate outcome, or estimate the possibility of, or amount or range of, any possible financial impact.
• Depending on the investigation's progress, there may be a material adverse impact on the company's business, results of operations, or financial condition.

Stakeholder Impact

• Shareholders: Potential for increased share price due to strong revenue growth and reduced losses, but also risk of volatility from legal proceedings and reimbursement uncertainties. Dilution from stock-based compensation plans is ongoing.
• Employees: Continued focus on recruitment, development, and retention through competitive compensation, benefits, and professional growth opportunities. Management changes, such as Anthony J. Recupero's transition, may impact internal dynamics.
• Customers (Physicians/Hospitals/ASCs): Expanded product portfolio and increased sales force support aim to enhance product adoption and surgical capacity. Clinical evidence from studies like SAFFRON and STACI provides confidence in product efficacy. However, uncertainty in reimbursement coding could affect adoption.
• Suppliers: Ongoing collaboration to reduce lead times and costs, but supply chain disruptions (e.g., titanium sourcing) and inflation pose challenges.
• Creditors: The company maintains compliance with debt covenants, and its liquidity position is deemed sufficient for the next 12 months, but potential future capital needs are noted.

Next Steps

• Continue to selectively expand the sales force, focusing on increasing sales managers' capacity and driving sales force productivity.
• Further engage with ambulatory surgery centers (ASCs) and Office-Based Labs (OBLs) to educate management groups on clinical evidence and payor coverage.
• Continue to invest in research and development initiatives to bring new and differentiated solutions to the market.
• Work closely with suppliers to reduce lead time for implants and build supply chain resilience.
• Integrate demand planning and manufacturing systems to leverage actual usage trends for surgical capacity planning.
• Monitor and respond to employee sentiment to enhance retention and job satisfaction, including providing ongoing learning and leadership training opportunities.

Key Dates

Recommendation

While SI-BONE, Inc. demonstrated strong revenue growth and a significant reduction in net loss and operating cash burn, indicating positive operational momentum, the ongoing Civil Investigative Demand from the U.S. Department of Justice regarding potential Anti-Kickback Statute and Civil False Claims Act violations introduces a material, unquantifiable risk. Additionally, uncertainties surrounding CPT code reimbursement changes could impact future demand. Given the strong operational performance balanced against these significant legal and regulatory uncertainties, a 'hold' recommendation is prudent. Investors should monitor developments in the DOJ investigation and reimbursement landscape closely.

Keywords

Medical devices, Sacroiliac joint, Spine surgery, Minimally invasive surgery, Orthopedics, Surgical implants, SEC filing, Financial results, SI-BONE, iFuse